RP

Rakeshkumar Maneklal Prajapati - Profile

Rakeshkumar Maneklal Prajapati, Director, with 4 companies across 2 industries.

About Rakeshkumar Maneklal Prajapati

Rakeshkumar Maneklal Prajapati has 1 years in corporate governance. Holds Director role. Currently with 1 company, including Amigen Biosciences Private Limited. Formerly with 3 companies, such as Vim Meditech Private Limited and Apister Lifesciences Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.

Current Companies 1
Past Companies 3
Total Affiliations 4
Oldest Company Age 1
Companies Associated with Rakeshkumar Maneklal Prajapati
Current Companies
Previous Companies

Explore Director's current and past company associations— Uncover their professional journey today!

Frequently Asked Questions
Who is Rakeshkumar Maneklal Prajapati?

Rakeshkumar Maneklal Prajapati has 1 years in corporate governance. Holds Director role. Currently with 1 company, including Amigen Biosciences Private Limited. Formerly with 3 companies, such as Vim Meditech Private Limited and Apister Lifesciences Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.

What is Rakeshkumar Maneklal Prajapati's role in current companies?

Rakeshkumar Maneklal Prajapati is associated with 1 company as Director.

What industries does Rakeshkumar Maneklal Prajapati specialize in?

Rakeshkumar Maneklal Prajapati has expertise in General Business, Technology.

How many years of experience does Rakeshkumar Maneklal Prajapati have?

Rakeshkumar Maneklal Prajapati has 1 years in corporate governance.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available